PubMed Health⌕ Search

PubMed · 11300831

Dodecamethyl-closo-dodecaborate(2-).

Abstract

Bis(tetraethylammonium) dodecamethyl-closo-dodecaborate(2-), [NEt(4)](2)[closo-B(12)Me(12)], [NEt(4)](2)2, was prepared employing modified Friedel-Crafts reaction conditions from [NEt(4)](2)[closo-B(12)H(12)], [NEt(4)](2)1, trimethylaluminum, and methyl iodide. The [NEt(4)](2)2 salt provides sufficient solubility in water to allow the synthesis of the important alkali metal salts A(2)2 (A = Li, Na, K, Rb, Cs) using cation-exchange procedures. The solid state structure of colorless [AsPh(4)](2)2 reveals a nearly perfect icosahedral B(12) cluster with B-B bonds ranging from 1.785(3) to 1.807(3) A and B-C bonds of 1.597(3)-1.625(3) A. In contrast, the crystal structure of dark-red [Py(2)CH(2)]2 (obtained from [NEt(4)](2)2 and [Py(2)CH(2)]Br(2)) contains a distorted icosahedral dianion [B-B = 1.740(13)-1.811(14) A, B-C = 1.591(13)-1.704(13) A]. In the [Py(2)CH(2)]2 salt, the dianion 2(2-) and its dipositive dipyridiniomethane counterion form a red charge-transfer complex. One-electron oxidation of 2(2)(-) by ceric(IV) ammonium nitrate affords the blue, air-stable radical [hypercloso-B(12)Me(12)](*-), dodecamethyl-hypercloso-dodecaborate(1-), 2(*-), isolated as the PPN salt. X-ray crystallography reveals that the geometries of the B(12) clusters observed in hypercloso-[PPN]2 and closo-[AsPh(4)](2)2 are identical and essentially undistorted icosahedra. The anion in the [PPN]2 structure contains B-B bonds ranging from 1.784(8) to 1.806(7) A and a range of B-C bonds from 1.596(7) to 1.616(7) A.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Peymann, C B Knobler, S I Khan, M F Hawthorne. 2001-03-12. Dodecamethyl-closo-dodecaborate(2-).. https://doi.org/10.1021/ic0010398

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗